



## **Emerald Health Pharmaceuticals to Participate at the Neurotech Investing & Partnering Conference**

SAN DIEGO, CA, May 15, 2019 – Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, will participate in a panel discussion at the Neurotech Investing & Partnering Conference on May 22, 2019 at the Renaissance Waterfront Hotel in Boston, MA. Dr. Jim DeMesa, Chief Executive Officer of EHP will give a presentation and participate on the panel, with details as follows:

**Session:** “Parkinson’s and Other Movement Disorders”

**Date and Time:** Wednesday, May 22, 2019 at 2:00 PM EDT

**Location:** Renaissance Waterfront Hotel, Boston, MA

The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry. For more information about this conference, please visit: <https://www.neurotechpartnering.com/>.

### **About Emerald Health Pharmaceuticals Inc.**

Emerald Health Pharmaceuticals is developing product candidates derived from cannabinoids for the treatment of CNS, autoimmune, and other diseases. The Company has two families of new chemical entities, derived from synthetic cannabidiol (CBD) and cannabigerol (CBG), that it has modified through rational drug design to affect validated receptors and pathways pertinent to targeted diseases. Its first drug candidate, EHP-101, is in Phase I clinical development and is focused on treating multiple sclerosis and systemic scleroderma. Its second drug candidate, EHP-102, is in preclinical development and is focused on treating Huntington’s disease and Parkinson’s disease. For more information, visit <http://www.emeraldpharma.life> or contact: [info@emeraldpharma.life](mailto:info@emeraldpharma.life).

*To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered "forward-looking statements," as described in the private securities litigation reform act of 1995, that reflect management's current beliefs and expectations. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "hope," "hypothesis," "intend," "may," "plan," "potential," "predict," "project," "should," "strategy," "will," "would," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop*

*our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.*